National Medicines Policy Review Committee and Terms of Reference

3 August 2021 - The National Medicines Policy has influenced a number of important strategies, frameworks and programs developed since ...

Read more →

National Medicines Policy Review will be significant for all Australians

30 July 2021 - Medicines Australia is eager to be part of a significant moment in history for Australian health ...

Read more →

Announcement of the National Medicines Policy Review Committee and Terms of Reference

30 August 2021 -  The Minister for Health has established an Expert Advisory Committee to lead the Review of the National ...

Read more →

PHARMAC releases drug wish-list to be more 'transparent' but advocates say it gives false hope

28 July 2021 - PHARMAC has for the first time released a list of all the drugs it wants to ...

Read more →

NHS England unveils new Innovative Medicine Fund

21 July 2021 - NHS England has unveiled its new Innovative Medicines Fund, to ensure patients have early access to ...

Read more →

ICER to test principle of fair access to fairly priced pharmaceuticals

2 July 2021 - The controversial approval last month by the FDA of Aduhelm (aducanumab) for patients with early-stage Alzheimer’s disease ...

Read more →

National Medicines Policy review to begin in August 2021

24 June 2021 - The review of the National Medicines Policy will begin in August 2021. ...

Read more →

Health equity and Medicaid transformation — operationalising President Biden’s agenda

19 June 2021 - President Biden has made reforms intended to “protect and strengthen Medicaid” a centrepiece of his health policy ...

Read more →

Let's have permanently quicker drug approvals

16 June 2021 - New drugs and vaccines likely to increase life expectancy, quality of life and save money, so we ...

Read more →

Shared decision making underpins good health care

17 June 2021 - Shared decision making between service users and health care professionals is an integral part of health care, ...

Read more →

ICER publishes protocol for first annual assessment of drug coverage policies that present barriers to fair access

25 May 2021 - ICER’s analysis, based on MMIT’s market access analytics solution, will evaluate how 15 of the largest ...

Read more →

Quebec announces intention to implement a biosimilar switching policy

18 May 2021 - Biosimilars Canada today congratulated the Government of Quebec and Minister of Health and Social Services Christian ...

Read more →

Sandoz Canada congratulates the Quebec government on implementing a shift towards biosimilars

18 May 2021 - The shift announced by Quebec will follow a similar approach to policies introduced in British Columbia, Alberta ...

Read more →

ICER publishes white paper evaluating policy options to strengthen FDA’s accelerated approval pathway for prescription drugs

26 April 2021 - Informed by expert input from patient groups, former regulators, payers, and life science companies, white paper analyses ...

Read more →

New Brunswick becomes third province in Canada to implement biosimilar switching policy

21 April 2021 - Biosimilars Canada today congratulated the Government of New Brunswick for implementing a biosimilar "switching" or transitioning ...

Read more →